Evolent Health, Inc (NYSE:EVH) – Research analysts at William Blair issued their Q1 2018 EPS estimates for Evolent Health in a research report issued on Monday. William Blair analyst R. Daniels forecasts that the technology company will post earnings per share of ($0.04) for the quarter. William Blair also issued estimates for Evolent Health’s Q2 2018 earnings at $0.01 EPS, Q3 2018 earnings at $0.02 EPS and Q4 2018 earnings at $0.04 EPS.
A number of other analysts also recently weighed in on the stock. Jefferies Group LLC reissued a “buy” rating and issued a $28.00 price target on shares of Evolent Health in a report on Wednesday, September 6th. SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $30.00 price objective on shares of Evolent Health in a report on Wednesday, September 20th. BidaskClub downgraded shares of Evolent Health from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. KeyCorp began coverage on shares of Evolent Health in a report on Tuesday, September 19th. They set an “overweight” rating and a $23.00 price objective for the company. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $35.00 price objective on shares of Evolent Health in a report on Wednesday, June 28th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $28.45.
TRADEMARK VIOLATION NOTICE: This news story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/10/28/equities-analysts-offer-predictions-for-evolent-health-incs-q1-2018-earnings-evh.html.
Evolent Health (EVH) traded down 0.469% during midday trading on Wednesday, hitting $15.925. 332,900 shares of the stock traded hands. Evolent Health has a 1-year low of $14.50 and a 1-year high of $27.50. The company has a 50-day moving average of $17.16 and a 200-day moving average of $17.16. The stock’s market cap is $1.05 billion.
Evolent Health (NYSE:EVH) last released its earnings results on Monday, August 7th. The technology company reported ($0.13) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.13). The company had revenue of $107.30 million during the quarter, compared to the consensus estimate of $104.45 million. Evolent Health had a negative net margin of 17.57% and a negative return on equity of 6.44%. The company’s revenue was up 89.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.20) EPS.
Institutional investors have recently made changes to their positions in the stock. ETF Managers Group LLC acquired a new stake in shares of Evolent Health during the 2nd quarter worth about $102,000. BNP Paribas Arbitrage SA increased its position in shares of Evolent Health by 815.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,751 shares of the technology company’s stock worth $120,000 after purchasing an additional 4,232 shares in the last quarter. US Bancorp DE increased its position in shares of Evolent Health by 0.3% during the 1st quarter. US Bancorp DE now owns 5,654 shares of the technology company’s stock worth $126,000 after purchasing an additional 19 shares in the last quarter. Point72 Asia Hong Kong Ltd acquired a new stake in shares of Evolent Health during the 1st quarter worth about $126,000. Finally, First Mercantile Trust Co. acquired a new stake in shares of Evolent Health during the 2nd quarter worth about $198,000. Institutional investors and hedge funds own 82.51% of the company’s stock.
In related news, COO Thomas Peterson III sold 40,540 shares of the stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $26.00, for a total transaction of $1,054,040.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Frank J. Williams sold 16,300 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $23.73, for a total transaction of $386,799.00. The disclosure for this sale can be found here. Insiders have sold a total of 62,840 shares of company stock valued at $1,588,679 over the last ninety days. 8.79% of the stock is owned by insiders.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.